ASX Announcement

14 October 2022

## Receipt of further R&D Tax Incentive Payment

Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY | FSE:AWY] would like to advise that further to the previous announcement on 14 April 2022 regarding receipt of an R&D Tax refund of $570,999, the Company has now received from the Australian Taxation Office a further R&D Tax Incentive refund of $909,040 in relation to eligible overseas expenditure under an approved Overseas Finding application, making a total received of $1,480,039 in relation to the 30 June 2021 financial year. The Overseas Finding application covers total eligible expenditure of $2.9M (the Company may claim up to 43.5% as a tax incentive refund, of which it has received $909,040 as above) and relates to the 2020-2021, 2021-2022 and 2022-2023 financial years.

**For more information please contact**:


**Antisense Therapeutics**
Mark Diamond
Managing Director
+61 (0)3 9827 8999
www.antisense.com.au

**Investment Enquiries**
Gennadi Koutchin
XEC Partners
gkoutchin@xecpartners.com.au
1300 932 037

**US/European IR & Media**
Laine Yonker/Joe Green
Edison Investor Relations
lyonker@edisongroup.com
+1 646-653-7035


*This announcement has been authorised for release by the Managing Director.*

**About Antisense Therapeutics Limited** [ASX: ANP | US OTC: ATHJY | FSE: AWY] is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.